QHSLab (USAQ) posts revenue and margin gains but faces heavy short-term debt, going-concern

QHSLab, Inc. (PINK: USAQ) - quick take

What's happening inside: revenue traction and product adoption are visible, but the company is highly leveraged, in default on multiple notes, and management warns of substantial doubt about going concern. Disclosure controls were assessed as ineffective.

Key facts & figures
- Revenue (Q2 2025): $605,446 vs $473,073 (Q2 2024).
- Revenue (6 months 2025): $1,250,865 vs $961,660 (6 months 2024).
- Gross profit (Q2 2025): $399,015; gross margin 65.9% (up from 62.2%).
- Gross profit (6 months 2025): $828,959; gross margin 66.3% (up from 60.4%).
- Net loss (Q2 2025): $(52,958) vs $(2,890).
- Net loss (6 months 2025): $(132,567) vs $(21,415).
- Interest expense (Q2 2025): $64,484 (driven by default interest); 6 months: $132,054.
- Cash & cash equivalents (6/30/2025): $168,358 (up from $157,168 at 12/31/2024).
- Current assets (6/30/2025): $385,980; Current liabilities: $2,354,356 → working capital ≈ $(1,968,376).
- Convertible notes payable (6/30/2025): $1,209,147 (all current).
- Total liabilities (6/30/2025): $2,354,356; Total stockholders' deficit: $(644,323); Accumulated deficit: $(4,463,917).
- Shares outstanding (8/14/2025): 11,281,527 common shares.

Positive aspects (income statement & operations)
- Top-line growth: Quarterly revenue increased ~28% year-over-year; six-month revenue up ~30% YoY.
- Improving gross margins: Q2 margin 65.9% and six-month margin 66.3% - product mix and higher-margin ISP services helped.
- Product diversification: Revenue from Allergy Diagnostic Kits, Integrated Service Program (ISP), Immunotherapy Treatments and a new Clinical Study revenue line ($89,100 recognized in H1 2025).
- Operating cash flow positive for the period: cash from operations $77,484 (six months), showing some cash generation despite net loss.

Negative aspects (income statement & risks)
- Widening net losses: net loss jumped materially (Q2 and YTD), driven primarily by rising interest expense and higher operating expenses (R&D, G&A, sales & marketing).
- Interest expense spike: interest doubled (and default interest at 18% applied) - interest expense was $132,054 for six months 2025 vs $64,986 prior year, materially increasing finance costs and losses.
- Heavy short-term leverage: all convertible debt and loans are current - $1.57M (current loans + convertible notes principal components recorded as current) contributes to a negative working capital position.
- Defaults and forbearance: Notices of default received on the $806,000 and $440,000 OID notes; those notes were assigned to Catheter (May 12, 2025). Management is negotiating restructures but enforcement risk remains.
- Going concern: management explicitly states substantial doubt about ability to continue as a going concern without financing or creditor forbearance.
- Controls weakness: CEO/CFO concluded disclosure controls and procedures were ineffective due to understaffing in financial reporting.

Operational trends to watch next
- Progress on note restructurings with Catheter and holder of the acquisition promissory note (forbearance status and any enforcement).
- Cash runway vs near-term current liabilities - large proportion of liabilities are current and could become collectible if creditors act.
- Trend in ISP adoption (ISP revenue grew 48.2% YTD) - continued growth there can improve margins and recurring revenue.
- Interest expense trajectory - any resolution lowering default interest will materially improve profitability.
- Any equity raises or debt conversions (dilution vs deleveraging tradeoff).

Bottom line: QHSLab (PINK: USAQ) shows real revenue momentum and improving gross margins driven by ISP and product mix, but financial health is fragile: high short-term debt, accrued default interest, negative working capital (~$1.97M short), going-concern disclosure, and ineffective disclosure controls. The story is growth with execution and financing risk - watch restructuring outcomes and cash runway closely.